- 25 November 2019
2:30 pm - 3:30 pm
Monday 25 November 2019, 2.30 pm – 3.30 pm
Auditorium, Level 6, Bancroft, QIMR Berghofer
Leadership: lessons from life in academia and industry
I have been privileged to have spent over 15 years in the USA and Europe working for large bio/pharma and start-up companies. Before that I spent a similar period of time in academia. As a result, I have had the opportunity to compare the strengths and the weaknesses of both environments, and consider what each might learn from the other. In this presentation, I will focus on Leadership and provide my perspective on elements we take for granted in academia, and contrast that with the expectations in industry. Academic credibility is an essential requirement for entry into industry. However, within a Company the clear focus is on generating new, approved products that will benefit patients. To achieve that goal, there is an emphasis on leadership, and the ability to build and motivate a team of individuals with diverse backgrounds, skills and expertise. While there is a strong focus on individual responsibility and accountability, the recognition is not for the individual but for the team. In addition, there is a sense of scientific humility that comes as a consequence of the repeated failures that are an essential part of experience in the clinic – the clinic is unforgiving. Unfortunately, these leadership attributes are often lacking within the academic environment, and in fact, are often under-valued, yet they are critical to ensuring that a group of intelligent, ambitious, motivated individuals work together to maintain focus and direction.
Dr C. Glenn Begley
Dr C. Glenn Begley is the inaugural CEO of BioCurate, a joint initiative of Monash and Melbourne Universities and created to provide commercial focus in the early phases of drug development. He served as Chief Scientific Officer at Akriveia Therapeutics, California (2016-2017) and TetraLogic Pharmaceuticals, Pennsylvania (2012-2016). From 2002-2012, he was Vice-President and Global Head of Hematology/Oncology Research at Amgen, responsible for building, directing and integrating Amgen’s 5 research sites. It was at Amgen he identified and highlighted the issue of research integrity and scientific reproducibility which has subsequently received considerable international attention. Before Amgen he had over 20 years of clinical experience in medical oncology and hematology. His personal research focused on regulation of hematopoietic cells and translational clinical trials. His early studies first described human G-CSF, and in later clinical studies, first demonstrated that G-CSF-”mobilized” blood stem cells hastened hematopoietic recovery. This finding revolutionized the clinical approach to bone-marrow transplantation. His honors include being elected as the first Foreign Fellow to the American Society of Clinical Investigation in 2000, to the Association of American Physicians in 2008, to the Research “Hall of Fame” at his alma mater, the Royal Melbourne Hospital in 2014, and to the Australian Academy of Health and Medical Sciences in 2016.
Cocktail function to follow
Registrations now closed